8-K: Passage Bio Reports First Quarter 2025 Financial Results and Provides Business Highlights

Passage Bio announced its Q1 2025 financial results, highlighting progress in its FTD-GRN program and a strengthened manufacturing process.

Summary

• Passage Bio reported its financial results for the first quarter ended March 31, 2025.
• The company treated the first FTD-GRN patient with Dose 2 PBFT02 and enrolled a second patient in the upliFT-D trial.
• Enrollment has opened for FTD-C9orf72 patients in the upliFT-D study.
• Passage Bio announced the presentation of process development data for a high productivity, suspension-based manufacturing process for PBFT02 at the ASGCT Annual Meeting.
• Cash, cash equivalents, and marketable securities totaled $63.4 million as of March 31, 2025, expected to fund operations into Q1 2027.
• Research and Development expenses were $7.7 million for the quarter ended March 31, 2025.
• General and Administrative expenses were $6.1 million for the quarter ended March 31, 2025.
• Net loss was $15.4 million, or $0.25 per basic and diluted share, for the quarter ended March 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical trials and has a strong cash position. However, it is still incurring significant losses and faces risks associated with drug development.

Positives

• Steady progress in executing core operational objectives, focusing on enrollment of FTD-GRN and FTD-C9orf72 patients.
• Robust CSF progranulin expression achieved at Dose 1 led to the introduction of Dose 2, which is 50% lower.
• Improved manufacturing process with higher productivity, capsid purity, and percentage of full capsids.
• Cash runway extended into Q1 2027.

Negatives

• The company reported a net loss of $15.4 million for the quarter ended March 31, 2025.
• Cash, cash equivalents and marketable securities decreased from $104.5 million as of March 31, 2024 to $63.4 million as of March 31, 2025.

Risks

• The company's ability to develop and obtain regulatory approval for its product candidates is subject to risks and uncertainties.
• Clinical trials are subject to risks, including the ability to adequately manage clinical activities and unexpected concerns that may arise from additional data or analysis.
• The company is dependent on collaborators and other third parties for the development and manufacture of product candidates.
• Current and potential delays, work stoppages, or supply chain disruptions could impact the company's operations.

Future Outlook

The company anticipates reporting 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on registrational trial design in the first half of 2026. They also expect their cash to fund operations into Q1 2027.

Management Comments

• We made steady progress in executing against our core operational objectives this quarter as we focus on the enrollment of FTD-GRN and FTD-C9orf72 patients in our ongoing global Phase 1/2 upliFT-D trial of PBFT02, said Will Chou, M.D., president and chief executive officer of Passage Bio.
• As we turn towards the second half of the year, we look forward to delivering additional data from upliFT-D to add to our understanding of PBFT02s safety profile, durability of progranulin expression, dose-response, and impact on plasma neurofilament levels, a disease progression biomarker that is well characterized in FTD natural history literature.
• We expect these data to foster meaningful engagement with health authorities in the first half of 2026 as we seek guidance on the registrational pathway for the program in FTD-GRN.

Industry Context

Passage Bio is focused on developing genetic medicines for neurodegenerative diseases, a field with significant unmet need. The company's lead product candidate, PBFT02, targets frontotemporal dementia (FTD), a disease with no approved disease-modifying therapies. The development of a high-productivity manufacturing process is crucial for late-stage development and potential commercialization.

Comparison to Industry Standards

• Passage Bio's PBFT02 aims to elevate CSF PGRN levels, with early data showing levels of 13-27 ng/mL at 6 months.
• Alector's data showed ~4-5 ng/mL with their anti-sortilin antibody.
• Lilly/Prevail's data showed ~4-8 ng/mL at 12 months with a higher dose of their AAV9 gene therapy.
• These comparisons suggest PBFT02 has the potential to achieve higher progranulin levels compared to other therapies in development.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and strong cash position are positive for shareholders.
• Patients: Advancements in PBFT02 development offer hope for patients with neurodegenerative diseases.
• Employees: Continued funding and progress support job security and growth opportunities.
• Creditors: The company's cash runway into Q1 2027 indicates a stable financial position.

Next Steps

• Evaluate Dose 2 in subsequent Cohort 2 patients.
• Report 12-month Dose 1 and interim Dose 2 data in 2H 2025.
• Seek regulatory feedback on registrational trial design in 1H 2026.
• Initiate dosing of FTD-C9orf72 patients in 1H 2025.
• Advance Huntingtons disease preclinical program.

Key Dates

Keywords

PBFT02, FTD-GRN, FTD-C9orf72, Frontotemporal Dementia, Gene Therapy, Progranulin, Clinical Trial, Financial Results, Passage Bio